Nevertheless, further in vivo study is required to clarify the molecular basis behind this, and test whether ERG, ATAD1, Wnt/β-catenin and lipid metabolism could be therapeutic targets in PRAD. This evidence concerns the gene ATAD1 and prostate adenocarcinoma.